CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenue:
Total revenue	$ 145	$ 142	$ 534	$ 250
Operating expenses:
Cost of sales	93	119	1,048	209
Research and development	651	700	1,300	1,556
Selling, general and administrative	216	230	389	442
Total operating expenses	960	1,049	2,737	2,207
Loss from operations	(815)	(907)	(2,203)	(1,957)
Interest income	67	81	139	171
Other (expense) income, net	(19)	8	(37)	4
Loss before income taxes	(767)	(818)	(2,101)	(1,782)
Provision for income taxes	15	7	24	14
Net loss	$ (782)	$ (825)	$ (2,125)	$ (1,796)
Net loss per share
Basic (in usd per share)	$ (1.97)	$ (2.13)	$ (5.36)	$ (4.64)
Diluted (in usd per share)	$ (1.97)	$ (2.13)	$ (5.36)	$ (4.64)
Weighted average common shares used in calculation of net loss per share
Basic (in shares)	398,000	388,000	396,000	387,000
Diluted (in shares)	398,000	388,000	396,000	387,000
Net product sales
Revenue:
Total revenue	$ 94	$ 114	$ 446	$ 200
Other revenue
Revenue:
Total revenue	$ 51	$ 28	$ 88	$ 50

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Operating activities
Net loss	$ (2,125)	$ (1,796)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	224	245
Depreciation and amortization	122	96
Amortization/accretion of investments	(21)	(37)
Loss on equity investments, net	2	8
Other non-cash items	10	36
Changes in assets and liabilities:
Accounts receivable, net	167	310
Prepaid expenses and other assets	70	(150)
Inventory	(126)	(122)
Right-of-use assets, operating leases	21	19
Accounts payable	(128)	(203)
Accrued liabilities	475	(395)
Deferred revenue	195	68
Operating lease liabilities	(15)	(10)
Other liabilities	(27)	(25)
Net cash used in operating activities	(1,156)	(1,956)
Investing activities
Purchases of marketable securities	(1,904)	(3,059)
Proceeds from maturities of marketable securities	1,442	3,424
Proceeds from sales of marketable securities	814	1,059
Purchases of property, plant and equipment	(99)	(120)
Purchase of intangible asset	0	(10)
Net cash provided by investing activities	253	1,294
Financing activities
Proceeds from issuance of common stock through equity plans	42	17
Tax payments related to net share settlements on equity awards	(4)	(1)
Changes in financing lease liabilities	(7)	(3)
Net cash provided by financing activities	31	13
Effect of changes in exchange rates on cash and cash equivalents	(1)	1
Net decrease in cash, cash equivalents and restricted cash	(873)	(648)
Cash, cash equivalents and restricted cash, beginning of year	2,597	1,929
Cash, cash equivalents and restricted cash, end of period	1,724	1,281
Non-cash investing and financing activities
Purchases of property and equipment included in accounts payable and accrued liabilities	36	47
Purchases of intangible asset included in accounts payable and accrued liabilities	$ 74	$ 0

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 1,723	$ 2,595
Investments	3,415	3,204
Accounts receivable, net	17	184
Inventory	280	153
Prepaid expenses and other current assets	380	408
Total current assets	5,815	6,544
Investments, non-current	1,772	2,336
Property, plant and equipment, net	2,059	2,134
Right-of-use assets, operating leases	697	719
Other non-current assets	618	605
Total assets	10,961	12,338
Current liabilities:
Accounts payable	167	317
Accrued liabilities	1,909	1,386
Deferred revenue	295	99
Other current liabilities	163	185
Total current liabilities	2,534	1,987
Deferred revenue, non-current	147	153
Operating lease liabilities, non-current	638	653
Financing lease liabilities, non-current	6	20
Long-term debt	591	590
Other non-current liabilities	284	285
Total liabilities	4,200	3,688
Commitments and contingencies (Note 12)
Stockholders’ equity:
Preferred stock, par value $0.0001; 162 shares authorized as of June 30, 2026 and December 31, 2025; no shares issued or outstanding at June 30, 2026 and December 31, 2025	0	0
Common stock, par value $0.0001; 1,600 shares authorized as of June 30, 2026 and December 31, 2025; 399 and 394 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	0	0
Additional paid-in capital	1,644	1,382
Accumulated other comprehensive income	19	45
Retained earnings	5,098	7,223
Total stockholders’ equity	6,761	8,650
Total liabilities and stockholders’ equity	$ 10,961	$ 12,338